Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.

Molecular pharmaceutics - 4 Aug 2014

Shen Song, Mao Chong-Qiong, Yang Xian-Zhu, Du Xiao-Jiao, Liu Yang, Zhu Yan-Hua, Wang Jun

Abstract excerpt

Synthetic lethal interaction provides a conceptual framework for the development of wiser cancer therapeutics. In this study, we exploited a therapeutic strategy based on the interaction between GATA binding protein 2 (GATA2) downregulation and the KRAS mutation status by delivering small interfering RNA targeting GATA2 (siGATA2) with cationic lipid-assisted polymeric nanoparticles for treatment of non-small-cell...

Topics

Join the communities discussing this publication.

Cations
GATA2 Transcription Factor
Hepatocytes
Mice, Nude
Microscopy, Confocal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 24521262
DOI: 10.1021/mp400714z

Genes

KRAS
GATA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.PMID 24521262Read ↗

Inhalable siRNA Nanoparticles for Enhanced Tumor-Targeting Treatment of KRAS-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Semantic proximity Read ↗

Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer.Semantic proximity Read ↗

Small RNA combination therapy for lung cancer.Semantic proximity Read ↗

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse modelSemantic proximity Read ↗

Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co-Mutant Tumors.Semantic proximity Read ↗

Lipid Nanoparticle Delivery of iMDK Induces ATF3-Mediated Apoptosis in Sotorasib-Resistant KRAS Mutant Lung Cancer.Semantic proximity Read ↗

Specific Inhibition of Viral MicroRNAs by Carbon Dots-Mediated Delivery of Locked Nucleic Acids for Therapy of Virus-Induced CancerSemantic proximity Read ↗

Interleukin-1β as target to induce synthetic lethality in KRAS mutant biliary tract cancer.Semantic proximity Read ↗

Advancements in gene therapy for lung cancer: from genetic insights to clinical applicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.